Project Grant R41CA224646

This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health (CFDA 93.286) program, provides $1,938,467 to Brigham & Women's Hospital Inc. to develop a catheter placement manipulator system to enable adaptive image-guided pelvic brachytherapy. The key products and services to be delivered include: (1) a fiber-optic shape-sensing stylet for real-time...

This federal Project Grant award of $670,440 was provided by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The grant supports the development of novel minimally invasive catheter-based devices called "functional endovascular filters" that can remove chemotherapy drugs from the blood to reduce systemic toxicity during locoregional infusion...

This federal Project Grant award of $374,095 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop a device that uses an infrared laser to enable local delivery of a high dose of chemotherapy to the surgical cavity after tumor resection. The technology employs thermosensitive liposomal nanoparticles encapsulating chemotherapy agents that...

The National Cancer Institute (NCI) awarded a $155,028 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Georgia Tech Research Corporation to develop an advanced 3D auxetic biodegradable implant for large volume breast reconstruction. The key products and services to be delivered under this 2-year grant include: Characterization and scaling up of a novel auxetic (re-entrant) architectural design for biodegradable breast implants to enhance flexibility, durability,...

This $255,730 National Science Foundation project grant supports the development of self-assembling molecular brachytherapy for treatment of metastatic cancer. The goal is to enable radiation therapies for metastatic cancer, which accounts for approximately 90% of cancer deaths in the United States each year. The grantee, Oncurie, LLC, seeks to advance a radiotherapy approach that exploits cancer cells themselves as catalysts for therapeutic delivery. Specifically, the company will develop an...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $703,540.00 to Brigham & Women's Hospital Inc. to develop and optimize highly effective treatments for head and neck cancer using in situ implantable microdevices. The primary goals are to: Conduct a clinical study to validate the performance of the microdevice in predicting patients' clinical response to immunotherapy and chemotherapy for head and neck squamous cell...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $857,315 to Creosalus Inc. to conduct a first-in-human clinical study evaluating the safety and efficacy of the company's Porous Brain Infusion Catheter (PBIC) system for convection-enhanced delivery of therapeutics to recurrent Grade 3-4 glioma patients. The primary objective is to assess the PBIC's safety profile and its ability to achieve significantly greater coverage of enhancing...

This $384,863 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" (CFDA 93.286) program supports research to develop a novel radiotracer imaging agent for detecting Gram-positive bacterial infections associated with implanted medical devices. The key products and services to be delivered include: In vitro testing of a bivalent radiotracer agent...

This $275,000 Small Business Technology Transfer (STTR) Phase I grant from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships program) was awarded to Oncoblaze LLC to develop a novel device for targeted delivery of chemotherapy agents to tissue surrounding surgically removed tumors. The project aims to address the issue of tumor recurrence after cancer surgery, which affects 30-40% of patients for certain cancers. The device uses an infrared laser to heat...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), provides $644,034 to develop a nanoparticle-based platform that uses radiation therapy to control the local and sustained release of chemotherapy drugs within irradiated tumor tissue. The overarching goal is to expand the therapeutic window of chemoradiation treatment by improving local disease...